Viscosupplementation is
a procedure in which hyaluronic acid (HA) is injected into the knee joint for
the treatment of osteoarthritis (OA) of the knee. HA is a naturally occurring
glycosaminoglycan and an integral component of synovial fluid and cartilage
matrix present in the joints.
Europe viscosupplementation market is estimated to account for US$
241.8 Mn in terms of value and is expected to reach US$
343.6 Mn by the end of 2027.
Europe
Viscosupplementation Market: Drivers
Increasing prevalence of OA is expected to propel growth of the
Europe viscosupplementation market over the forecast period. For instance,
according to the study, ‘Prevalence and development of hip and knee osteoarthritis according
to American College of Rheumatology criteria in the CHECK cohort’, published in
January 2019, in BMC Arthritis Research & Therapy, 63% of the participants
in the Netherlands suffered from hip OA and 92% of participants with knee
complaints were classified as having knee OA.
Moreover, increasing geriatric population is also expected to aid in
growth of the market. For instance, according to Office of National Statistics,
U.K. 2018, there are nearly 12 million people aged 65 and above in the U.K. of
which 5.4 million people are aged over 75, 1.6 million are aged over 85, over
500,000 people are over 90, and 14,430 are centenarians.
Three injection cycle held dominant position in Europe
viscosupplementation market in 2019, accounting for 59.5% share
in terms of value, followed by five injection cycle, and single injection
cycle, respectively
Europe Viscosupplementation Market:
Opportunities
R&D related to viscosupplements is expected to
offer lucrative growth opportunities for players in Europe viscosupplementation
market. For instance, in May 2018, researchers from Humboldt-Universität zu Berlin
and Berlin Institute of Health, Germany, reported that HA can influence the
cartilage metabolism via upregulation of Metalloproteinase inhibitor 3 in
OA-like condition.
In Europe, there has been a rise in the number of
osteoarthritis patients seeking alternate options to knee replacement in view
of avoiding the side effects associated with NSAID and corticosteroids
injections. This factor has changed the overall scenario in the pharmaceuticals
industry, propelling the inclination of the players in the market towards the
viscosupplementation-based therapy.
Comments
Post a Comment